Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer

Lung Cancer

Volumn 79, Issue 1, 2013, Pages 20-26

  Hotta, Katsuyuki ^a   Suzuki, Etsuji ^b   Di Maio, Massimo ^c   Chiodini, Paolo ^d   Fujiwara, Yoshiro ^a   Takigawa, Nagio ⁱ   Ichihara, Eiki ^a   Reck, Martin ^e   Manegold, Christian ^f   Pilz, Lothar ^g   Hisamoto Sato, Akiko ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a   Shepherd, Frances A ^h   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e KRANKENHAUS GROSSHANSDORF   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ Kawasaki Hospital   (Japan)

Author keywords

Non small cell lung cancer; Overall survival; Progression free survival; Surrogate marker

Indexed keywords

AFATINIB; BEVACIZUMAB; CEDIRANIB; CELECOXIB; CETUXIMAB; ERLOTINIB; GEFITINIB; REBIMASTAT; ROFECOXIB; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CORRELATIONAL STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871037359     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.007     Document Type: Article

References (36)

1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909.
2. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:3852-3859.
3. Hotta K., Matsuo K. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2007, 2:96.
4. Hotta K., Fujiwara Y., Matsuo K., Suzuki T., Kiura K., Tabata M., et al. Recent improvement in the survival of patients with advanced non-small-cell lung cancer enrolled in phase III trials of first-line systemic chemotherapy. Cancer 2007, 109:939-948.
5. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
6. Federal Drug Administration. Guidance for industry: clinical trial endpoints for the approval of non-small cell lung cancer drugs and biologics (June 2011).
7. Soria J.C., Massard C., Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Ann Oncol 2010, December (21):2324-2332.
8. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
9. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
10. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
11. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
12. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
13. Yamanaka T., Okamoto T., Ichinose Y., Oda S., Maehara Y. Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol 2006, 11:167-175.
14. A dictionary of epidemiology 2008, Oxford University Press, New York, NY. 5th ed. M.S. Porta (Ed.).
15. Hotta K., Kiura K., Takigawa N., Fujiwara Y., Tabata M., Tanimoto M. Progression-free survival (PFS) and overall survival (OS) in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2010, (abstr #7624).
16. Hotta K., Fujiwara Y., Matsuo K., Kiura K., Takigawa N., Tabata M., et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009, 4:311-317.
17. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
18. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang C, Zhang S, Ren S, on behalf of the OPTIMAL investigators. Efficacy results from the randomized phase III OPITIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced nonsmall-cell lung cancer patients (PTS) with EGFR activating mutations. Ann Oncol 2010; 21 (Suppl.; LBA13).
19. Chu T.-M., Weir B., Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002, 176:35-51.
20. Hotta K., Kiura K., Fujiwara Y., Takigawa N., Oze I., Ochi N., et al. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 2009, 20:829-834.
21. Hotta K., Kiura K., Fujiwara Y., Takigawa N., Hisamoto A., Ichihara E., et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systemic review. Plos ONE 2011, 6:e26646.
22. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
23. Matthews J.N.S. Introduction to randomized controlled clinical trials 2006, Chapman & Hall/CRC, Boca Raton, FL. 2nd ed.
24. Korn E.L., Freidlin B., Abrams J.S. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011, 29:2439-2442.
25. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649.
26. Wakelee H.A., Bernardo P., Johnson D.H., Schiller J.H. Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group Trials before and after 1990. Cancer 2006, 106:2208-2217.
27. Ng R., Loreto M., Lee R., Leighl N.B. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 2008, 61:262-265.
28. Hanna N. Advances in the treatment of second-line non-small-cell lung cancer. Lung Cancer 2005, 50(Suppl. 1):S15-S17.
29. Hotta K., Kiura K., Takigawa N., Fujiwara Y., Tabata M., Ueoka H., et al. Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer 2008, 62:236-241.
30. Hotta K., Kiura K., Toyooka S., Takigawa N., Soh J., Fujiwara Y., et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 2007, 2:632-637.
31. Freidlin B., Korn E.L., Hunsberger S., Gray R., Saxman S., Zujewski J.A. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007, 25:2122-2126.
32. Kato Y., Ichihara E., Hotta K., Hisamoto A., Takigawa N., Nogami N., et al. Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience. J Clin Oncol 2012, 30. Suppl. [abstr 7576].
33. EMA European Medicines Agency (ema), Committee for Medicinal Products for Human Use. Guideline on the evaluation of anticancer medicinal products in Man. London, U.K.: EMA; 2006.
34. Piedbois P., Buyse M. Meta-analysis based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004, 22:3839-3841.
35. Matsuo K., Hotta K., Ueoka H. They also serve who stand and wait-do individual clinical researchers too?.: Hope for individual patient data as public domain. J Clin Oncol 2005, 23:1334-1335.
36. Buyse M., Burzykowski T., Carroll K., Michiels S., Sargent D.J., Miller L.L., et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 20(25):5218-5224.